Oregon Health and Science University
Open enrollment across a mixed-phase pipeline
According to ClinicalTrials.gov-derived indexes, Oregon Health and Science University sits in the top decile of US sponsors by registered trial count (#67 of 15,742 sponsors by registered trial count).
Oregon Health and Science University: 546 sponsored US clinical trials, 91 recruiting.
Oregon Health and Science University sponsors 546 registered US clinical trials on ClinicalTrials.gov, 91 of them currently recruiting, and 370 completed. 73 of these trials are in Phase 3-4 (later-stage) and 92 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Obesity, with 6 trials.
Top-decile sponsor footprint
Oregon Health and Science University ranks in the top decile of sponsors by registered trial count (#67 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
370 of 420 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (88.1%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
546 total, page 2 of 11
Characterizing Iodine-124 Evuzumitide (AT-01) in Systemic Amyloidosis
NCT05758493
Disparities in Emergency Contraceptive Metabolism Dictate Efficacy
NCT05674513
The Work-life Check-ins: a Supervisor-driven Intervention to Reduce Burnout in Primary Care
NCT05436548
Effect of Abdominal Wall Injections on Abdominal Pain
NCT06121466
Safety and Target Engagement of Centella Asiatica in Cognitive Impairment
NCT05591027
Vestibulectomy Surgical Techniques Comparison Study
NCT05343182
Balance Tele-Rehab in Parkinson's Disease Parkinson's Disease
NCT05680597
Sleep and Circadian Mechanisms in Hypertension
NCT05184933
Comparative Effectiveness of Cryoablation Versus Steroid and Lidocaine Alone for Treatment of Morton's Neuroma
NCT05501262
Bringing Weight Management Into the Primary Care Pediatric Practice
NCT05950620
Early Augmentative and Alternative Communication (AAC) Intervention Delivered Via Hybrid Telehealth
NCT05743439
IUD Self-Removal Study
NCT05339555
Single-dose Intravenous Iron Therapy for Anemia After Orthopaedic Trauma
NCT05292001
Food and Circadian Timing
NCT04743271
Reducing Intraoperative ESKAPE Transmission Through Use of a Personal Hand Hygiene System
NCT04900298
Correlation Between Intraoperative Tourniquet Use and Limb pH, Functional Measures and Patient-reported Outcomes After Ankle Fracture Surgery
NCT05445960
Sleep Duration and Cardiovascular Health
NCT04804124
Hypertonic Saline for MAC
NCT04921943
Directional Versus Nondirectional DBS for ET
NCT04828798
Brown Adipose Tissue Activation by Spinal Cord Stimulation
NCT04326192
Scleral Lens Fitting Using Wide-Field OCT
NCT04570020
OCT in Fuchs' Dystrophy
NCT04258787
Effects of a Specific Substance in Smokers
NCT04281979
Transcranial Magnetic Stimulation in Progressive Supranuclear Palsy
NCT04468932
OCT Angiography and NRAI in Dementia
NCT03761381
Collagen Cross-linking in Keratoconus
NCT03760432
Observational Study of Iris Tumors
NCT03809585
Augmentation of Limb Perfusion With Contrast Ultrasound
NCT03195556
OCT in Diagnosis of Irregular Corneas
NCT03504800
rTMS for Craving in Methamphetamine Use Disorder
NCT03470480
OCT Angiography in Wet AMD
NCT02253030
OCT in Rare Chorioretinal Diseases
NCT02141308
Eye Pressure Lowering Surgery
NCT01931904
Lovenox 30 mg Twice Daily (BID) Versus 40 mg Once Daily (QD)
NCT02342444
Reaching Out to Distressed Medical Residents, Fellows and Faculty
NCT02010866
Functional and Structural Imaging for Glaucoma
NCT01957267
Pacemaker and Defibrillator Lead Extraction Registry
NCT03847025
VAPORHCS/OHSU J: MRI and Devices
NCT03915015
Clinical and Genetic Analysis of ROP
NCT04420156
Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy
NCT01243931
Intraocular Lens Power Calculation After Laser Refractive Surgery Based on Optical Coherence Tomography
NCT00532051
Chlorhexidine Lavage for Recurrent Urinary Tract Infection
NCT06598514
Piloting a School-Based Distress Tolerance Skills Program for Adolescents
NCT06638853
The Over The Counter Pill National Study
NCT05988983
Autism ALERT Expansion
NCT06246890
Peer Engagement in Methamphetamine Harm-Reduction With Contingency Management (PEER-CM)
NCT05700994
Evaluation of Lower Extremity Athletic Injuries and Response to Treatment Using SWE and MFI
NCT05608824
COMmunity of Practice And Safety Support for Navigating Pain (COMPASS-NP)
NCT05492903
The COVID-19 VaccinE Response and Co-Administration in Rheumatology Patients (COVER-CoAd)
NCT05543642
Mobility in Daily Life and Falls in Parkinson's Disease: Potential for Rehabilitation
NCT04897256
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 52 |
| Phase 2 | 40 |
| Phase 3 | 6 |
| Phase 4 | 67 |
Therapeutic Areas
What is open in the Oregon Health and Science University pipeline
91 recruiting of 546 indexed (17% open); 370 completed (68%).
Phase mix: 73 late (III/IV) vs 92 early (I/II) (balanced across stages).
Top condition: Obesity (6 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Oregon Health and Science University: open-pipeline peers nationwide
Peers matched on 546 registered trials and 17% open enrollment, not the therapeutic-area sidebar.
Oregon Health and Science University sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 546 trials (± recruiting share)
- Ohio State University · 552 trials · 21% recruiting
- Amgen · 558 trials · 10% recruiting
- Merck Sharp & Dohme · 558 trials · 22% recruiting
- Virginia Commonwealth University · 558 trials · 14% recruiting
Sponsors near 17% open enrollment (± trial volume)
- Adagene · 17% recruiting · 6 trials
- Agendia · 17% recruiting · 6 trials
- Akamis Bio · 17% recruiting · 6 trials
- Angiodynamics · 17% recruiting · 12 trials
Related
What to do with this Oregon Health and Science University page
546 registered trials is a research-attention snapshot, not an endorsement of Oregon Health and Science University or any single study.
- 91 of Oregon Health and Science University's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Obesity is the condition Oregon Health and Science University studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Obesity trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Oregon Health and Science University pipeline card: 546 registered trials from official public datasets.Report a data error.